INVESTOR OVERVIEWCorporate ProfileRhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. More >>Recent NewsMore >>08/08/18Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results07/23/18Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity06/25/18Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares RYTM (Common Stock) $31.73 1.28 (4.20%)08/17/18 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and SourcesUpcoming EventsMore >>There are currently no events scheduled.